Spectranetics Concludes LARS Trial

COLORADO SPRINGS, Colo., Nov. 28 -- The Spectranetics Corp. said it is concluding its LARS (laser angioplasty for restenosed stents) clinical trial, in light of recent approval from the FDA to market its products to clear clogged coronary stents (thin steel mesh tubes used to support the walls of arteries) prior to radiation treatment.

The company will continue to follow all 138 LARS patients through the study's nine-month follow-up period. It said its clinical priorities for 2002 continue to be accelerating PELA and LACI clinical trials involving excimer laser energy to clear blockages in leg arteries.